In vivo characterization of inflammatory biomarkers in swine and the impact of flunixin meglumine administration

Veterinary Immunology and Immunopathology

Volumn 148, Issue 3-4, 2012, Pages 236-242

  Peters, Sharla M ^a,b   Yancy, Haile ^a   Deaver, Christine ^a   Jones, Yolanda L ^a   Kenyon, Elizabeth ^a   Chiesa, Oscar A ^a   Esparza, Juan ^a   Screven, Rudell ^a   Lancaster, Vicki ^a   Stubbs, John T ^b   Yang, Maocheng ^a   Wiesenfeld, Paddy L ^a   Myers, Michael J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HOWARD UNIVERSITY   (United States)

Author keywords

Biomarkers; Inflammation; Non steroidal anti inflammatory drugs; Swine

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; CD1 ANTIGEN; CD4 ANTIGEN; FLUNIXIN MEGLUMINE; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; SERUM AMYLOID A2 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BARROW (SWINE); CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTAGLANDIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD1; ANTIGENS, CD4; BIOLOGICAL MARKERS; CASPASE 1; CHEMOKINE CCL2; CLONIXIN; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; REAL-TIME POLYMERASE CHAIN REACTION; SERUM AMYLOID A PROTEIN; SWINE; SWINE DISEASES; THROMBOXANE B2;

ANIMALIA; ESCHERICHIA COLI; SUIDAE;

EID: 84865042073     PISSN: 01652427     EISSN: 18732534     Source Type: Journal    
DOI: 10.1016/j.vetimm.2012.05.001     Document Type: Article

References (32)

1. Anonymous, 1998. Freedom of information summary. Supplemental new animal drug application. NADA 101-479. Banamine injectable solution. (accessed 04.03.12). http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm064905.pdf.
2. Atkinson A.J., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Hoth D.F., Oates J.A., Peck C.C., Schooley R.T., Spilker B.A., Woodcock J., Zeger S.L. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
3. Bryant C.E., Farnfield B.A., Janicke H.J. Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa B. Am. J. Vet. Res. 2003, 64:211-215.
4. Bubhoff U., Hein A., Iglesias A., Dorries R., Regnier-Vigouroux A. CD1 expression is differentially regulated by microglia, macrophages, and T cells in the central nervous system upon inflammation and demyelination. J. Neuroimmunol. 2001, 113:220-230.
5. Buckland M., Jago C.B., Fazekasova H., Scott K., Tan P.H., George A.J.T., Lechler R., Lombardia G. Aspirin-treated human DCs up-regulate ILT-3 and induce hyporesponsiveness and regulatory activity in responder T cells. Am. J. Transplant. 2006, 6:2046-2059.
6. Bufan B., Mojsilović S., Vučićević D., Vučević D., Vasilijić S., Balint B., čolić M. Comparative effects of aspirin and NO-releasing aspirins on differentiation, maturation and function of human monocyte-derived dendritic cells in vitro. Int. Immunopharmacol. 2009, 9:910-917.
7. Chun T., Wang K., Zuckermann F.A., Gaskins H.R. Molecular cloning and characterization of a novel CD1 gene from the pig. J. Immunol. 1999, 162:6562-6571.
8. EMA, 2011. European medicines agency, metacam scientific discussion. (accessed 01.03.12). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Scientific_Discussion/veterinary/000033/WC500065773.pdf.
9. Gagliardi M.C., Teloni R., Mariotti S., Iona E., Pardini M., Fattorini L., Orefici G., Nisini R. Bacillus Calmete-Guerin shares with virulent Mycobacterium tuberculosis the capacity to subvert monocyte differentiation into dendritic cell: implication for its efficacy as a vaccine preventing tuberculosis. Vaccine 2004, 22:3848-3857.
10. Gagliardi M.C., Lemassu A., Teloni R., Mariotti S., Sargentini V., Pardini M., Daffe M., Nisin R. Cell wall-associated alpha-glucan is instrumental for Mycobacterium tuberculosis to block CD1 molecule expression and disable the function of dendritic cell derived from infected monocyte. Cell. Microbiol. 2007, 9:2081-2092.
11. Hackstein H., Morelli A.E., Larregina A.T., Ganster R.W., Papworth G.D., Logar A.J., Watkins S.C., Falo L.D., Thomson A.W. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J. Immunol. 2001, 166:7053-7062.
12. Hava D.L., van der Wel N., Cohen N., Dascher C.C., Houben D., Leon L., Agarwal S., Sugita M., van Zon M., Kent S.C., Shama H., Peters P.J., Brenner M.B. Evasion of peptide, but not lipid antigen presentation through pathogen-induced dendritic cell maturation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11281-11286.
13. Landoni M.F., Cunningham F.M., Lees P. Determination of pharmacokinetics and pharmacodynamics of flunixin in calves by use of pharmacokinetic/pharmacodynamic modeling. Am. J. Vet. Res. 1995, 56(6):786-794.
14. Lees P., Landoni M.F., Giraudel J., Toutain P.L. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. J. Vet. Pharmacol. Ther. 2004, 27:479-490.
15. Malle E., DeBeer F.C. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur. J. Clin. Invest. 1996, 26:427-435.
16. Mariotti S., Teloni R., Iona E., Fattorinin L., Romagnoli G., Gagliardi M.C., Orefici G., Nisini R. Mycobacterium tuberculosis diverts alpha interferon-induced monocyte differentiation from dendritic cells into immunoprivileged macrophage-like host cells. Infect. Immun. 2004, 72:4385-4392.
17. Matasicâ R., Dietz A.B., Vuk-Pavlovic S. Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology 2000, 101:53-60.
18. Myers M.J., Farrell D.E., Baker J.D., Evock-Clover C.M., Steele N.C. Endotoxin challenge differentially affects cytokine production and metabolic status of growing and finishing swine. Domest. Anim. Endocrinol. 1999, 17:345-360.
19. Myers M.J., Farrell D.E., Palmer D.C., Post L.O. Inflammatory mediator production in swine following endotoxin-challenge with or without co-administration of dexamethasone. Int. Immunopharmacol. 2003, 3:571-579.
20. Peters S.M., Yancy H., Bremer E., Monroe J., Paul D., Stubbs J., Myers M.J. In vitro identification and verification of inflammatory biomarkers in swine. Vet. Immunol. Immunopathol. 2011, 139:67-72.
21. Roura-Mir C., Wang L., Cheng T.-Y., Matsunaga I., Dascher C.C., Peng S.L., Fenton M.J., Kirschning C., Moddy D.B. Mycobacterium tuberculosis regulates CD1 antigen presentation pathways through TLR-2. J. Immunol. 2005, 175:1758-1766.
22. Salerno A., Herman R. Efficacy and safety of steroid use for postoperative pain relief. J. Bone Joint Surg. 2006, 88A:1361-1372.
23. Schmid-Schonbein G.W. Analysis of inflammation. Annu. Rev. Biomed. Eng. 2006, 8:93-151.
24. Steel D.M., Whitehead A.S. The major acute phase reactants: C-reactive protein, serum Amyloid P component and serum amyloid A protein. Immunol. Today 1994, 15:81-88.
25. Steel D.M., Whitehead A.S. Heterogeneous modulation of acute-phase-reactant mRNA levels by interleukin-1β and interleukin-6 in the human hepatoma cell line PLC/PRF/5. Biochem. J. 1991, 277:477-482.
26. Stenger S., Niazi K.R., Modlin R.L. Down-regulation of CD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis. J. Immunol. 1998, 161:3582-3588.
27. Švajger U., Vidmar A., Jeras M. Niflumic acid renders dendritic cells tolerogenic and up-regulates inhibitory molecules ILT3 and ILT4. Int. Immunopharmacol. 2008, 8:997-1005.
28. Takada Y., Bhardwaj A., Potdar P., Aggarwal B.B. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004, 23:9247-9258.
29. Teige A., Teige I., Lavasani S., Bockermann R., Mondoc E., Holmdahl R., Issazadeh-Navikas S. CD-1 dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis. J. Immunol. 2004, 172:186-194.
30. Tegeder I., Pfeilschifter J., Geisslinger G. Cyclooxygenase-independent actions of cylooxygenase inhibitors. FASEB J. 2001, 15:2057-2072.
31. Uhlar C.M., Whitehaead A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Clin. Pharmacol. 1999, 265:501-523.
32. Vane J.R., Botting R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am. J. Med. 1998, 104(3A):2-8.